A surprising negative CRL on July 17th will result in disaster for shareholders, but I don't see this as the outcome. Orexigen Therapeutics, Inc. (OREX) has a drug called Contrave that received a majority vote for approval from an FDA advisory panel in early 2011 sending the stock soaring, only to later crash after the FDA rejected approval and cited the need for further studies relating to the affects on the heart. Its development and commercialization partner Takeda Pharmaceuticals (TYO: 4502) is still hopeful that Contrave will eventually be approved and in February, an agreement was reached with (DMEP) Division of Metabolic and Endocrinology Products via an (SPA) Special Protocol Assessment with regards to a (CVOT) Cardiovascular Outcomes Trial, expected to last through 2014. With a current market cap of $233 million, I consider Orexigen to be dead money for quite some time and it's better this issue gets revisited in mid 2013, so until then, simply hit the snooze button.